FDA advisers endorse J&J's canagliflozin for diabetes

01/10/2013 | Wall Street Journal, The

An FDA panel recommended the approval of Johnson & Johnson's Invokana, or canagliflozin to treat type 2 diabetes in a 10-5 vote. Some advisers suggested that patients with impaired kidneys should be told not to take the drug.

View Full Article in:

Wall Street Journal, The

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Executive Officer
CarePoint Health Plan
Jersey City, NJ
Regional Director, Southeastern Region - State Affairs
America's Heatlh Insurance Plans (AHIP)
Washington, DC
Assistant General Counsel
Cardinal Health
Chicago, IL
Pharmacy Care Manager
National Association of Chain Drug Stores
Arlington, VA
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC